지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2016.1
- 수록면
- 80 - 87 (8page)
이용수
초록· 키워드
오류제보하기
Purpose This study aimed to evaluate the efficacy and safety of pemetrexed versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy.
Materials and Methods Patients with advanced (stage IIIB or IV) or recurrent NSCLC were randomly assigned to receive either 500 mg/m! of pemetrexed intravenously every 3 weeks or gefitinib 250 mg/day orally. The primary end point was progression-free survival (PFS) at 6 months.
Results A total of 95 patients were enrolled (47 for pemetrexed and 48 for gefitinib). Most patients were male (72%) and current/ex-smokers (69%), and 80% had non-squamous cell carci- noma. The epidermal growth factor receptor (EGFR) mutation status was determined in 38 patients (40%); one patient per each arm was positive for EGFR mutation. The 6-month PFS rates were 22% and 15% for pemetrexed and gefitinib, respectively (p=0.35). Both arms showed an identical median PFS of 2.0 months and a median overall survival (OS) of 8.5 months. In EGFR wild-type patients, higher response rate (RR) and longer PFS as well as OS were achieved via pemetrexed compared with gefitinib, although there were no signifi- cant differences (RR: 39% vs. 9%, p=0.07; median PFS: 6.6 months vs. 3.1 months, p=0.45; median OS: 29.6 months vs. 12.9 months, p=0.62). Toxicities were mild in both treatment arms. Frequently reported toxicities were anemia and fatigue for pemetrexed, and skin rash and anorexia for gefitinib.
Conclusion Both pemetrexed and gefitinib had similar efficacy with good tolerability as second-line treat- ment in unselected patients with advanced NSCLC. However, pemetrexed is considered more effective than gefitinib for EGFR wild-type patients.
목차
등록된 정보가 없습니다.
참고문헌 (23)
참고문헌 신청
정규원 / 2013 / Cancer Statistics in Korea: Incidence, Mortality, Survival and Prevalence in 2010 / Cancer Research and Treatment 45(1):1~14
Siegel R / 2013 / Cancer statistics, 2013 / CA Cancer J Clin 63:11~30
Govindan R / 2006 / Changing epidemiology of small-cell lung cancer in the United States over the last 30 years : analysis of the surveillance, epidemiologic, and end results database / J Clin Oncol 24:4539~4544
Azzoli CG / 2011 / 2011 Focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-celllung cancer / J Clin Oncol 29:3825~3831
Azzoli CG / 2009 / American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-smallcell lung cancer / J Clin Oncol 27:6251~6266
Siegel R / 2013 / Cancer statistics, 2013 / CA Cancer J Clin 63:11~30
Govindan R / 2006 / Changing epidemiology of small-cell lung cancer in the United States over the last 30 years : analysis of the surveillance, epidemiologic, and end results database / J Clin Oncol 24:4539~4544
Azzoli CG / 2011 / 2011 Focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-celllung cancer / J Clin Oncol 29:3825~3831
Azzoli CG / 2009 / American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-smallcell lung cancer / J Clin Oncol 27:6251~6266
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
Cancer Research and Treatment
2019 .01
-
Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis
Tuberculosis and Respiratory Diseases
2018 .01
-
EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Non-squamous Non-small Cell Lung Cancer
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Thyroid Transcription Factor-1 Expression in Advanced Non-Small Cell Lung Cancer: Impact on Survival Outcome
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase-Low Squamous Cell Lung Cancer
Cancer Research and Treatment
2021 .01
-
Pemetrexed in Treating Patients with Metastatic Bladder Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Pemetrexed Induces G1 Phase Arrest and Apoptosis through Inhibiting Akt Activation in Human Non Small Lung Cancer Cell Line A549
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Study of Pemetrexed-based Chemotherapy for Patients with Locally Advanced or Metastatic Cancers
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations
Cancer Research and Treatment
2015 .01
-
Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial
Cancer Research and Treatment
2015 .01
-
Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer
Yonsei Medical Journal
2018 .01
-
Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT
Cancer Research and Treatment
2015 .01
-
Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer
Cancer Research and Treatment
2017 .01
-
The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer
Cancer Research and Treatment
2015 .01
-
Meta-analysis of Seven Randomized Control Trials to Assess the Efficacy and Toxicity of Combining EGFR-TKI with Chemotherapy for Patients with Advanced NSCLC who Failed First-Line Treatment
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status
Cancer Research and Treatment
2017 .01
-
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
Cancer Research and Treatment
2022 .04
-
Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey
Journal of Pathology and Translational Medicine
2015 .01
-
Cell Free EGFR mRNA Expression and Implications for Survival and Metastasis in Non-Small Cell Lung Cancer Cases
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Low-dose Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body Surface Area
Asian Pacific journal of cancer prevention : APJCP
2016 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0